Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H16O6.C17H19ClN2S |
Molecular Weight | 707.234 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2.OC(=O)C4=CC5=C(C=CC=C5)C(CC6=C7C=CC=CC7=CC(C(O)=O)=C6O)=C4O
InChI
InChIKey=LCKBXWYKBWCAOP-UHFFFAOYSA-N
InChI=1S/C23H16O6.C17H19ClN2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h1-10,24-25H,11H2,(H,26,27)(H,28,29);3-4,6-9,12H,5,10-11H2,1-2H3
DescriptionSources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdfCurator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/op000018u | https://www.drugs.com/pro/chlorpromazine.html
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
Curator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/op000018u | https://www.drugs.com/pro/chlorpromazine.html
Chlorpromazine pamoate (also known as chlorpromazine embonate) is a salt of pamoic acid and a chlorpromazine. Pamoate salts are used in pharmaceutical formulations because they show slow dissolution and are useful in formulations where extended duration of action is required. Chlorpromazine is a phenothiazine antipsychotic. It also exerts sedative and antiemetic activity. The precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. It has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and antimuscarinic activities. Chlorpromazine is a dopamine inhibitor; the turnover of dopamine in the brain is also increased. There is some evidence that the antagonism of central dopaminergic function, especially at the D2-dopaminergic receptor, is related to therapeutic effect in psychotic conditions.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2056 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf |
56.0 nM [Ki] | ||
Target ID: CHEMBL217 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf |
19.0 nM [Kd] | ||
Target ID: CHEMBL231 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf |
9.0 nM [Kd] | ||
Target ID: CHEMBL2094251 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf |
2.6 nM [Kd] | ||
Target ID: CHEMBL2095158 Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf |
750.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HIBERNAL Approved UseFor the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness. |
|||
Primary | HIBERNAL Approved UseFor the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness. |
|||
Primary | HIBERNAL Approved UseFor the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness. |
Sample Use Guides
In Vivo Use Guide
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf https://www.drugs.com/dosage/chlorpromazine.html
Acute Schizophrenia/Manic States: usual dose for adults is 500 mg/day.
Nausea/Vomiting: usual dose for adults is 10 to 25 mg every 4 to 6 hours as needed.
Light Sedation: usual dose for adults is 25 to 50 mg 2 to 3 hours before the operation.
Chlorpromazine embonate 144 mg is equivalent to about 100 mg of chlorpromazine hydrochloride.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7918347
The inhibition-dissociation constant (Ki) of a number of neuroleptics for D1 receptors of normal human brain tissue was determined. Phenothiazines ranged from 10 nM to 250 nM, and Ki value for chloropromazine was 56 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000088281
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
261-487-5
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
3085150
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
DTXSID10207644
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
58901-20-5
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
85RG9X8ZHE
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY | |||
|
SUB01254MIG
Created by
admin on Fri Dec 15 22:07:11 GMT 2023 , Edited by admin on Fri Dec 15 22:07:11 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD